Elliott Management Takes Aim at Phillips 66 Board with Director Nominations and Governance Proposal

by | Mar 4, 2025

Elliott Investment Management has fired another shot in its campaign to overhaul Phillips 66 (NYSE: PSX), nominating seven independent director candidates to the company’s board as it filed its preliminary proxy. The activist investor, which now holds a more than $2.5 billion stake in the refining and midstream giant, has also proposed a governance policy change that would move the company toward annual board elections—an issue that has seen strong but so far ineffective shareholder support in recent years.

Phillips tops the list of companies in the energy sector at risk from activists based on Boardroom Alpha’s Activist Risk score. Given its underperformance, activist risk profile, and governance issues — staggered board, multiple directors receiving low support from shareholders, non-independent chair, a history of say-on-pay questions — we weren’t surprised to see Elliott make a big push. CEO Mark Lashier has now been on the job for almost 3 years and while the stock has bounced under his tenure, the direction has been negative over the past year with the stock down -9%.

Elliott’s Push for Change

Elliott has been vocal about what it sees as persistent underperformance at Phillips 66. In its public letter to the board on February 11, the firm laid out a three-pronged plan aimed at unlocking value:

  • Portfolio Simplification: Focusing on Phillips 66’s most profitable assets and shedding underperforming or non-core businesses.
  • Operating Review: Identifying efficiencies and performance improvements in refining and midstream operations.
  • Enhanced Oversight: Strengthening board oversight and accountability to ensure long-term shareholder value creation.

The nomination of new board members, Elliott argues, is essential to advancing these initiatives and ensuring the company finally makes meaningful progress.

Who Are Elliott’s Nominees?

Elliott’s slate includes a mix of industry veterans with experience in refining, midstream operations, capital allocation, and governance:

  • Brian Coffman – Former CEO of Motiva Enterprises and former SVP of Refining at Andeavor.
  • Sigmund Cornelius – Former SVP and CFO of ConocoPhillips.
  • Michael Heim – One of the founders and former President and COO of Targa Resources.
  • Alan Hirshberg – Former EVP, Production, Drilling, and Projects at ConocoPhillips.
  • Gillian Hobson – Former M&A and Capital Markets Partner at Vinson & Elkins, with significant expertise in midstream transactions.
  • Stacy Nieuwoudt – Former Energy and Industrials Analyst at Citadel.
  • John Pike – Partner at Elliott Investment Management.

Phillips 66’s Response and Board Uncertainty

The nominations come just weeks after Phillips 66 announced that two of its current directors, Gary Adams and Denise Ramos, would not stand for re-election, and that the board would shrink from 14 to 12 members after the 2025 annual meeting. However, the company has yet to clarify how many board seats will be contested or who it intends to nominate. Adams and Ramos have both been at PSX for over 8 years.

This uncertainty gives Elliott room to adjust its final slate ahead of the definitive proxy filing, potentially allowing for further negotiations or boardroom maneuvering.

The Governance Battle: Push for Annual Elections

In addition to its board challenge, Elliott has submitted a proposal aimed at shifting Phillips 66 to an annual director election model. Over the past nine years, the company has repeatedly put forward proposals to declassify the board—most recently in 2023, when 99% of shares voted in favor—but these efforts have failed due to an 80% supermajority requirement for a charter amendment.

Elliott’s new proposal seeks to bypass this structural hurdle by requesting that the board adopt a corporate governance policy requiring each director to commit to a one-year term at each annual meeting. While not a formal declassification, the move would effectively create annual elections, aligning Phillips 66 with modern governance best practices and increasing board accountability to shareholders.

What’s Next?

With a significant stake and a detailed plan, Elliott is making it clear that it intends to push hard for change at Phillips 66. Vanguard, Blackrock, and State Street are the largest shareholders so the retail component of the campaign will be important. Elliott is using long-time advisor Okapi Partners, who has a long and successful track record for contested situations, as its proxy solicitor. The company’s response—whether through engagement with Elliott or a firm defense of its existing board structure—will be closely watched by investors and governance watchers alike.

Recent Analysis

Weekly Boardroom & Executive Moves: May 1, 2026

This week, significant leadership changes occurred across several companies facing financial difficulties. Abbott Laboratories (ABT) and Agilon Health Inc (AGL) appointed new board members and executives amidst high activist risks and declining TSRs. Accuray Inc (ARAY) and ALT5 Sigma Corp (ALTS) also saw key executive departures and appointments as they navigate substantial TSR declines. These shifts highlight the ongoing challenges and strategic redirections needed to stabilize operations and improve shareholder value.

Daily SPAC Update – May 1, 2026

Two SPAC IPOs launched today, raising a total of $500 million. CH4 Natural Solutions Acquisition Corp (MTNE) secured $300 million, while Quantum Leap Acquisition Corp (QLEP) raised $200 million. Today, 2 SPAC IPOs raised $500M, led by CH4 Natural Solutions (MTNE) at $300M. This follows a surge of activity at the end of April.

Daily SPAC Update – April 30, 2026

Today, six SPACs debuted, raising a total of $965 million. General Catalyst Global Resilience Merger Corp (GCGR) led the pack with $350 million, followed by RRE Ventures Acquisition Corp. (RREV) at $250 million. Month-to-date, SPAC IPOs total 16, bringing in $2.65 billion, compared to 11 IPOs last month that raised $1.72 billion.

Daily SPAC Update – April 29, 2026

Collective Acquisition Corp. II (CAII) launched its $220 million IPO today, targeting high-potential sectors like technology and healthcare. In executive moves, Roger Bendelac was appointed CEO of both Drugs Made in America Acquisition Corp (DMAA) and Drugs Made in America Acquisition II Corp (DMII), with Saleem Elmasri as CFO. Meanwhile, General Purpose Acquisition Corp (GPAC) saw a significant decline of 22.9%, closing at $9.96, while Aimei Health Technology Co Ltd (AFJK) gained 2.7% to $46.12.

Daily SPAC Update – April 28, 2026

SPAC IPOs Look Stalled Again as Irenic’s $220M IPO Only Makes it Seven. Miluna Acquisition + CADV.AI Deal. Prophyte Extension Vote to Add 12 More Months.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.